{
  "component_scores": {
    "joint_involvement": {
      "score": 5,
      "justification": "Patient facts mention polyarthrite rhumatoïde (polyarticular arthritis) and the presence of RF, which suggests involvement of more than 10 joints. Additionally, the patient is on methotrexate as a csDMARD."
    },
    "serology": {
      "score": 3,
      "justification": "The presence of positive RF (value: positive) qualifies for 3 points under Category B guidelines."
    },
    "acute_phase": {
      "score": 1,
      "justification": "CRP value is known and is 32 mg/L, which exceeds the threshold to score as 1 point."
    },
    "duration": {
      "score": 0,
      "justification": "Chronic/long-standing RA status is mentioned in patient facts, but no specific duration information was provided. This does not warrant a score of 1 unless more details are available."
    }
  },
  "acr_eular_total": 9,
  "treatment_context": {
    "has_dmard": true,
    "treatment_strength": "strong",
    "justification": "The patient is on methotrexate, which is a csDMARD and considered strong evidence for established RA."
  },
  "final_label": "RA+",
  "classification_rationale": "Patient meets the criteria for ACR-EULAR 2010 classification with a total score of 9/10. The high score in both joint involvement (5 points) and serology (3 points), combined with strong treatment evidence from methotrexate, strongly supports a diagnosis of RA+.",
  "confidence": "high",
  "patient_id": "0007",
  "agent": "Agent2_LLM_Reasoning_BALANCED",
  "retrieved_guidelines": [
    {
      "title": "Clinical Context",
      "content": "Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "text": "Clinical Context Treatment patterns provide additional evidence:\n- Methotrexate (MTX) = first-line csDMARD\n- Biologic DMARDs (anti-TNF, anti-IL6, etc.) = established RA\n- JAK inhibitors = treatment-refractory RA\n\nIn clinical practice:\n- Score ≥6/10 = definite RA\n- Score 4-5/10 + DMARD treatment = probable established RA\n- Score ≥5/10 without treatment = borderline, likely RA",
      "relevance_score": 4.683000883810066
    },
    {
      "title": "Category B: Serology (0-3 points)",
      "content": "- Negative RF AND negative ACPA: 0 points\n- Low-positive RF OR low-positive ACPA (≤3× ULN): 2 points\n- High-positive RF OR high-positive ACPA (>3× ULN): 3 points\n\nRF = Rheumatoid Factor\nACPA = Anti-citrullinated protein antibody (anti-CCP)\nULN = Upper limit of normal (typically RF: 20 IU/mL, anti-CCP: 10 U/mL)",
      "text": "Category B: Serology (0-3 points) - Negative RF AND negative ACPA: 0 points\n- Low-positive RF OR low-positive ACPA (≤3× ULN): 2 points\n- High-positive RF OR high-positive ACPA (>3× ULN): 3 points\n\nRF = Rheumatoid Factor\nACPA = Anti-citrullinated protein antibody (anti-CCP)\nULN = Upper limit of normal (typically RF: 20 IU/mL, anti-CCP: 10 U/mL)",
      "relevance_score": 3.7519987234196357
    },
    {
      "title": "Category A: Joint Involvement (0-5 points)",
      "content": "- 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "text": "Category A: Joint Involvement (0-5 points) - 1 large joint: 0 points\n- 2-10 large joints: 1 point\n- 1-3 small joints (with or without large joints): 2 points\n- 4-10 small joints (with or without large joints): 3 points\n- >10 joints (at least 1 small joint): 5 points\n\nLarge joints: shoulders, elbows, hips, knees, ankles\nSmall joints: MCPs, PIPs, MTPs (2nd-5th), thumb IPs, wrists",
      "relevance_score": 2.188326647736484
    }
  ],
  "guideline_citation": "Aletaha D, et al. Arthritis Rheum. 2010;62(9):2569-2581",
  "evidence_trace": [
    {
      "type": "disease_mention",
      "stay_id": null,
      "line_no": "005",
      "snippet": "Diagnostic évoqué : polyarthrite rhumatoïde probable, mais anti-CCP négatif."
    },
    {
      "type": "disease_mention",
      "stay_id": null,
      "line_no": "005",
      "snippet": "Diagnostic évoqué : polyarthrite rhumatoïde probable, mais anti-CCP négatif."
    },
    {
      "type": "disease_mention",
      "stay_id": null,
      "line_no": "005",
      "snippet": "Diagnostic évoqué : polyarthrite rhumatoïde probable, mais anti-CCP négatif."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0013",
      "line_no": 5,
      "snippet": "Diagnostic évoqué : polyarthrite rhumatoïde probable, mais anti-CCP négatif."
    },
    {
      "type": "disease_mention",
      "stay_id": null,
      "line_no": "004",
      "snippet": "Diagnostic : polyarthrite rhumatoïde confirmée."
    },
    {
      "type": "disease_mention",
      "stay_id": "S0014",
      "line_no": 4,
      "snippet": "Diagnostic : polyarthrite rhumatoïde confirmée."
    },
    {
      "type": "lab",
      "test": "RF",
      "stay_id": null,
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 32 mg/L, VHS 55 mm/h, RF : positif à 110 UI/mL, anti-CCP : négatif (<5 U/mL)."
    },
    {
      "type": "lab",
      "test": "anti-CCP",
      "stay_id": null,
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 32 mg/L, VHS 55 mm/h, RF : positif à 110 UI/mL, anti-CCP : négatif (<5 U/mL)."
    },
    {
      "type": "lab",
      "test": "CRP",
      "stay_id": null,
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 32 mg/L, VHS 55 mm/h, RF : positif à 110 UI/mL, anti-CCCP : négatif (<5 U/mL)"
    },
    {
      "type": "lab",
      "test": "VHS",
      "stay_id": null,
      "line_no": "003",
      "snippet": "Laboratoire (J1) : CRP 32 mg/L, VHS 55 mm/h, RF : positif à 110 UI/mL, anti-CCCP : négatif (<5 U/mL)"
    },
    {
      "type": "lab",
      "test": "CRP",
      "stay_id": null,
      "line_no": "002",
      "snippet": "Laboratoire (J1) : CRP 58 mg/L, VHS 70 mm/h."
    },
    {
      "type": "lab",
      "test": "anti-CCP",
      "stay_id": null,
      "line_no": "003",
      "snippet": "anti-CCP : rétesté à 28 U/mL (positif)."
    },
    {
      "type": "lab",
      "test": "VHS",
      "stay_id": null,
      "line_no": "002",
      "snippet": "Laboratoire (J1) : CRP 58 mg/L, VHS 70 mm/h."
    },
    {
      "type": "drug",
      "name": "methotrexate",
      "stay_id": null,
      "line_no": "006",
      "snippet": "Prise en charge : début de méthotrexate 15 mg/semaine."
    }
  ]
}